Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium infantis BX-01 metabolites
- Development stage
- Unknown
- Lead developer
- Inner Mongolia Autonomous Region People's Hospital
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium infantis BX-01 metabolites are postbiotic substances produced during the fermentation of the specific probiotic strain Bifidobacterium infantis BX-01. These metabolites are being investigated for their therapeutic potential in managing irritable bowel syndrome (IBS). Clinical research, primarily led by the Inner Mongolia People's Hospital, evaluates the effects of these metabolites on IBS symptoms, intestinal mucosal barrier function, gut microbiota composition, and inflammatory markers. As postbiotics, these metabolites represent the bioactive compounds secreted by live bacteria that can confer health benefits to the host without the need for the administration of live microorganisms.
- Other names
- Bifidobacterium infantis BX-01 postbioticsB. infantis BX-01 metabolites
02
Targets
FFAR2FFAR3 (Free fatty acid receptor 3)HDAC (HDAC family)
Beyond the preview
Go deeper on Bifidobacterium infantis BX-01 metabolites.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium infantis BX-01 metabolites.